Opportunity Information: Apply for PA 16 073
Apply for PA 16 073
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Behavioral and Integrative Treatment Development Program (R34)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273, 93.279,.
- This funding opportunity was created on Jan 08, 2016 and posted on Jan 08, 2016.
- Applicants must submit their applications by Jan 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $225,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Behavioral and Integrative Treatment Development Program (R34) (Funding Opportunity Number PA-16-073) is a discretionary NIH grant opportunity under HHS (Agency: HHS-NIH11) designed to support early-stage, clearly scoped research projects that can be finished within a three-year period. The program is aimed at helping investigators develop and refine behavioral interventions, as well as integrated approaches that combine behavioral strategies with other modalities such as pharmacological treatment. The central idea is to fund focused “Stage I†treatment development work that lays a strong foundation for later, larger-scale efficacy or effectiveness studies.
The scientific focus is on intervention development related to four key areas: substance abuse, HIV prevention among people in substance abuse treatment (specifically preventing acquisition or transmission), improving adherence to substance abuse treatment and to HIV/addiction medications, and chronic pain. In practical terms, applications should propose research that creates, adapts, or optimizes interventions that can meaningfully change these outcomes, especially in real-world settings where adherence and implementation challenges are common.
A major emphasis of this FOA is on Stage I behavioral treatment development. This includes (1) Stage I intervention generation, meaning the initial design or creation of an intervention, and (2) Stage I pilot or feasibility studies, meaning small-scale testing to determine whether the approach is workable, acceptable, and promising enough to justify larger trials. Importantly, both types of studies are expected to go beyond simply delivering an intervention and measuring outcomes. Applicants are encouraged to explicitly develop and examine putative targets and the “why†and “how†of change, including potential moderators (for whom the intervention works best), mediators (pathways through which the intervention works), and mechanisms of behavior change. This reflects NIH’s interest in interventions that are theory-informed and empirically grounded rather than purely pragmatic bundles of activities.
The FOA also highlights the need for intervention development that fits into primary care. This includes Stage I efforts to generate or refine substance use treatment or adherence interventions that can be delivered or supported in primary care environments, which often require shorter, more streamlined, and more implementable approaches than traditional specialty treatment settings. Along the same lines, the announcement encourages projects that aim to “boost†intervention impact while also increasing implementability. Examples mentioned include creative use of technology or other strategies to make interventions easier to deliver, easier to scale, and more likely to be adopted in routine practice (for instance, digital tools, telehealth components, automated supports, or other delivery innovations).
From an administrative standpoint, the funding instrument is a grant, with an award ceiling listed at $225,000. Eligibility is broad and includes many types of domestic organizations, such as state, county, city/township, and special district governments; independent school districts; public and private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (outside higher education); for-profit organizations other than small businesses; and small businesses (with a note indicating other entities may be eligible depending on NIH’s additional eligibility language). The opportunity is associated with CFDA numbers 93.273 and 93.279. The FOA was posted and created on January 8, 2016, and the listed closing date for the cycle shown is January 7, 2019.
Overall, this R34 opportunity is best understood as a targeted NIH mechanism for advancing promising behavioral and integrated interventions from concept to early testing, with a strong expectation that applicants will define clear change targets and generate evidence about feasibility and mechanisms. It is oriented toward producing well-justified, implementable interventions for substance use, HIV-related risk and prevention in treatment populations, adherence to treatment and medications, and chronic pain, positioning successful projects for subsequent larger trials and broader public health impact.
Frequently Asked Questions (FAQs)
What is the Behavioral and Integrative Treatment Development Program (R34)?
The Behavioral and Integrative Treatment Development Program (R34) is a discretionary NIH grant opportunity under HHS (Agency: HHS-NIH11). It supports early-stage, clearly scoped research projects focused on developing and refining behavioral interventions, including integrated approaches that combine behavioral strategies with other treatment modalities (such as pharmacological treatment).
What is the funding opportunity number for this program?
The funding opportunity number is PA-16-073.
What kind of projects is this FOA designed to support?
This FOA is designed to support early-stage treatment development work (described as "Stage I") that is focused and can be completed within a three-year period. The intent is to generate a strong foundation for later, larger-scale efficacy or effectiveness studies.
How long is the expected project period?
Projects are expected to be clearly scoped so they can be finished within a three-year period.
What is meant by "Stage I" treatment development in this FOA?
"Stage I" refers to early treatment development activities that move an intervention from concept toward initial testing. The FOA emphasizes two main categories: (1) Stage I intervention generation (initial design/creation of an intervention) and (2) Stage I pilot or feasibility studies (small-scale testing to assess whether the approach is workable, acceptable, and promising enough to justify larger trials).
What are the main scientific focus areas supported by this opportunity?
The FOA highlights intervention development related to four key areas: substance abuse; HIV prevention among people in substance abuse treatment (specifically preventing acquisition or transmission); improving adherence to substance abuse treatment and to HIV/addiction medications; and chronic pain.
Does the FOA support interventions aimed at HIV prevention?
Yes. One of the stated focus areas is HIV prevention among people in substance abuse treatment, specifically work aimed at preventing acquisition or transmission.
Does the FOA include medication-related topics?
Yes. The FOA explicitly includes improving adherence to HIV/addiction medications, and it also supports integrated approaches that combine behavioral strategies with other modalities such as pharmacological treatment.
What types of outcomes or impacts are applications expected to target?
Applications should propose research that creates, adapts, or optimizes interventions intended to meaningfully change outcomes related to substance use, HIV prevention in treatment populations, adherence to treatment and medications, and chronic pain, with attention to real-world settings where adherence and implementation challenges are common.
Is the program only about delivering an intervention and measuring outcomes?
No. The FOA emphasizes that Stage I studies should go beyond simply delivering an intervention and measuring outcomes. Applicants are encouraged to explicitly develop and examine putative targets and the "why" and "how" of change.
What does the FOA mean by examining the "why" and "how" of change?
It refers to building theory-informed and empirically grounded interventions by identifying and studying putative targets and mechanisms, including potential moderators (for whom the intervention works best), mediators (pathways through which the intervention works), and mechanisms of behavior change.
Are moderators and mediators specifically encouraged in proposed research?
Yes. The FOA encourages applicants to examine moderators, mediators, and mechanisms of behavior change as part of understanding how and why an intervention works.
What is the FOA's stance on theory-informed interventions?
The FOA reflects NIH's interest in interventions that are theory-informed and empirically grounded, rather than purely pragmatic bundles of activities.
Does this FOA encourage intervention development for primary care settings?
Yes. The FOA highlights the need for intervention development that fits into primary care, including Stage I efforts to generate or refine substance use treatment or adherence interventions that can be delivered or supported in primary care environments.
Why is primary care specifically emphasized?
Primary care settings often require shorter, more streamlined, and more implementable approaches than traditional specialty treatment settings. The FOA encourages intervention development that can work within those constraints.
Does the FOA encourage making interventions easier to implement and scale?
Yes. The announcement encourages projects that aim to boost intervention impact while also increasing implementability, including approaches intended to make interventions easier to deliver, easier to scale, and more likely to be adopted in routine practice.
Are technology-based or digital intervention components relevant to this FOA?
Yes. Examples mentioned include creative use of technology or other strategies that improve delivery and scalability, such as digital tools, telehealth components, automated supports, or other delivery innovations.
What is the funding instrument for this opportunity?
The funding instrument is a grant.
What is the award ceiling listed for this opportunity?
The award ceiling listed is $225,000.
Who is the sponsoring agency?
The sponsoring agency is HHS-NIH11 (NIH under the U.S. Department of Health and Human Services).
What types of organizations are eligible to apply?
Eligibility is broad and includes many types of domestic organizations, including: state governments; county governments; city or township governments; special district governments; independent school districts; public and private institutions of higher education; federally recognized tribal governments; other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (outside higher education); for-profit organizations other than small businesses; and small businesses. The FOA also notes that other entities may be eligible depending on NIH's additional eligibility language.
Are tribal governments and tribal organizations included in the eligible applicant types?
Yes. Federally recognized tribal governments and other tribal organizations are listed among eligible applicants.
Are for-profit organizations eligible to apply?
Yes. For-profit organizations other than small businesses are listed as eligible, and small businesses are also listed as eligible.
Are nonprofit organizations eligible to apply even if they do not have 501(c)(3) status?
Yes. The eligibility list includes nonprofits with or without 501(c)(3) status (outside higher education).
What CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA numbers 93.273 and 93.279.
When was this FOA posted and created?
The FOA was posted and created on January 8, 2016.
What is the closing date listed for the cycle shown?
The listed closing date for the cycle shown is January 7, 2019.
What is the overall goal of the R34 program as described in this FOA?
The overall goal is to advance promising behavioral and integrated interventions from concept to early testing, with a strong expectation that applicants define clear change targets and generate evidence about feasibility and mechanisms, positioning successful projects for subsequent larger trials and broader public health impact.
Browse more opportunities from the same category: Education, Health
Next opportunity: Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01)
Previous opportunity: Strengthening Local Capacity to Provide Sustainable HIV-Related Care and Treatment Services in South Africa under PEPFAR
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 16 073
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 16 073) also looked into and applied for these:
| Funding Opportunity |
|---|
| Clinical Development of Minimally-Invasive Bioassays to Support Outpatient Clinical Trials of Therapeutics for Substance Use Disorders (R01) Apply for PA 16 076 Funding Number: PA 16 076 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $500,000 |
| Behavioral Science Track Award for Rapid Transition (B/Start)(R03) Apply for PAR 16 071 Funding Number: PAR 16 071 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $75,000 |
| Behavioral and Integrative Treatment Development Program (R01) Apply for PA 16 072 Funding Number: PA 16 072 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 16 084 Funding Number: PAR 16 084 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $275,000 |
| Supplements to Promote Clinical Research Studies on Pediatric Burkitt Lymphoma in Low- and Middle-Income Countries (Admin Supp) Apply for PA 16 086 Funding Number: PA 16 086 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $100,000 |
| Imaging and Biomarkers for Early Cancer Detection (U01) Apply for PAR 16 089 Funding Number: PAR 16 089 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics toward Commercialization (R44) Apply for RFA CA 16 008 Funding Number: RFA CA 16 008 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
| Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (U01) Apply for PAR 16 105 Funding Number: PAR 16 105 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $400,000 |
| Services Planning Research in the Appalachian Region to Address Adverse Health Consequences Associated with Increased Opioid Injection Drug Use (R03) Apply for RFA DA 16 015 Funding Number: RFA DA 16 015 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $100,000 |
| Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01) Apply for PAR 16 111 Funding Number: PAR 16 111 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Increased Knowledge and Innovative Strategies to Reduce HIV Incidence-iKnow Projects (R01) Apply for PAR 16 117 Funding Number: PAR 16 117 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R21) Apply for PAR 16 123 Funding Number: PAR 16 123 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3) Apply for RFA DA 17 015 Funding Number: RFA DA 17 015 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $1,000,000 |
| Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (R01) Apply for PAR 16 122 Funding Number: PAR 16 122 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| The Application of Big Data Analytics to Drug Abuse Research (R01) Apply for PA 16 119 Funding Number: PA 16 119 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Emerging Questions in Cancer Systems Biology (U01) Apply for PAR 16 131 Funding Number: PAR 16 131 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Cancer Research Education Grants Program to Promote Diversity - Research Experiences (R25) Apply for PAR 16 138 Funding Number: PAR 16 138 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| The Early Detection Research Network: Biomarker Developmental Laboratories (U01) Apply for RFA CA 16 009 Funding Number: RFA CA 16 009 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Coordinating Center for Barrett's Esophagus Translational Research Network (BETRNet)(U24) Apply for RFA CA 16 007 Funding Number: RFA CA 16 007 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $250,000 |
| Cancer Research Education Grants Program to Promote Diversity - Courses for Skills Development (R25) Apply for PAR 16 139 Funding Number: PAR 16 139 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 073", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.